HES3

Across TCGA pan-cancer cohorts, HES3 RNA is linked to patient survival in 18 of 34 cancer types, making it the most broadly survival-associated HES3 data layer compared with 1 for mutation status.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher HES3 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated HES3 expression acts as an unfavorable survival marker, although some lineages such as LUAD and UVM show a favorable association.

LIHC, READ, and THCA are the cancer types where HES3 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	All	0.321	0.699	<.001	150	view →
READ	OS	Tertile	II,III,IV	0.667	0.932	<.001	96	view →
THCA	OS	Tertile	All	0.974	0.990	.001	87	view →
DLBC	DFS	Tertile	All	0.353	0.956	<.001	65	view →
LUAD	DFS	Tertile	All	0.711	0.305	.002	60	view →
UVM	DFS	Tertile	II,III,IV	0.944	0.636	.002	50	view →
LAML	DFS	Median	All	0.533	0.225	<.001	50	view →
LGG	OS	Tertile	All	0.709	0.839	<.001	33	view →
OV	OS	Tertile	All	0.248	0.338	.016	30	view →
ACC	DFS	Tertile	All	0.199	0.606	.006	24	view →
SCLC	DFS	Quartile	All	0.238	0.886	.002	13	view →
SKCM	OS	Quartile	IV	0.128	0.711	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 18 lineages.

HES3–LIHC (OS)

Open the LIHC breakdown →